Cardiac fibrosis is the pathological accumulation of extracellular matrix proteins in the heart, a process orchestrated primarily by fibroblasts. When the heart is stressed by pressure overload, myocardial infarction, or chronic inflammation, quiescent fibroblasts activate into myofibroblasts, cells that proliferate, migrate, contract, and deposit large quantities of collagen and other matrix components. In the short term this response is protective, patching damaged tissue and preserving the structural integrity of the ventricular wall. When the signal never shuts off, however, the accumulating scar stiffens the myocardium, impairs electrical conduction, and gradually pushes the heart toward diastolic dysfunction and heart failure. Clinically, no approved therapy directly targets this process; existing treatments manage hemodynamic load and neurohormonal activation while fibrosis progresses.

PTBP1, polypyrimidine tract binding protein 1, is one of the cell’s most influential splicing factors. Alternative splicing allows a single gene to yield multiple protein isoforms by including or excluding different RNA segments, and PTBP1 binds specific sequence motifs on precursor messenger RNA to tip these decisions. Beyond splicing, PTBP1 participates in RNA stability, translation, and even transcript localization, and it is famous in regenerative biology for its ability, when silenced, to help convert non-neuronal cells into neuron-like cells. Its role in the heart’s fibrotic armory, however, has been far less clear, and the new study set out to test whether fibroblast PTBP1 is a bystander or an active participant in scarring.

To resolve that question, the investigators generated mice in which PTBP1 was deleted selectively in cardiac fibroblasts, sidestepping the developmental and neuronal roles of the protein that complicate whole-animal knockout approaches. This cell-type-specific strategy is essential because PTBP1 is broadly expressed; removing it everywhere would produce a tangle of secondary effects impossible to attribute to fibroblasts. With the deletion restricted to the scar-forming population, the researchers could ask a clean question: when fibroblasts lose their master splicing regulator, does the fibrotic response to cardiac stress change, and if so, how?

The answer was yes, and the mechanism was legible at the level of the transcriptome. Fibroblasts lacking PTBP1 showed broad alterations in alternative splicing, and among the affected transcripts were genes central to the profibrotic program. The splice isoforms produced in the knockout cells differed from those made in wild-type fibroblasts in ways that modulated the cells’ sensitivity to the cytokine TGF-beta, the dominant driver of myofibroblast differentiation, and to the downstream signaling that activates collagen production and contractility. In effect, removing the splicing factor rewired the interpretive layer between the fibrotic signals a cell receives and the proteins it deploys in response.

This outcome matters conceptually because much of fibrosis research has concentrated on transcriptional control, asking which transcription factors activate fibrotic genes and which signaling cascades converge on their promoters. The PTBP1 data demonstrate that post-transcriptional regulation constitutes a second, largely independent control layer. A gene can be transcribed at a normal rate yet produce a protein with altered function if its exons are assembled differently. In fibroblasts, that assembly step is influenced heavily by PTBP1, meaning the intensity and character of the scarring response can be tuned without changing gene expression in the conventional sense.

Technically, the study illustrates the current standard toolkit for dissecting splicing in vivo. RNA sequencing of fibroblasts isolated from control and knockout animals allowed the team to quantify splicing changes genome-wide, identifying skipped exons, alternative splice sites, and shifted isoform ratios across thousands of transcripts. These molecular maps were then connected to cellular phenotypes measured in culture and to the intact organ in models of cardiac stress, an approach that links a molecular event, exon usage, all the way through to tissue-level consequences. It is exactly this chain of evidence, from factor to isoform to cell behavior to organ pathology, that turns a correlation into a credible regulatory mechanism.

One of the most interesting implications concerns isoform switching as a therapeutic concept. If individual fibrotic genes exist in profibrotic and less-pathological isoforms, then future interventions might not need to silence a gene outright, which is often toxic because genes rarely have a single role. Instead, drugs could be designed to nudge splicing decisions toward protective isoforms. Splice-switching oligonucleotides, short synthetic molecules that bind pre-mRNA and redirect the splicing machinery, are already approved for neuromuscular disease and are being explored in cardiology. A validated role for PTBP1 in the fibrotic response provides a concrete molecular handle for that class of strategy in heart disease.

The work also adds to a growing literature on RNA-binding proteins as disease genes. Over the past decade, RNA processing factors have been implicated in cardiomyopathy, congenital heart disease, and cardiac aging, but fibroblasts have received less attention than cardiomyocytes in this respect. Given that fibroblasts compose the majority of non-muscle cells in the heart and are the chief effectors of remodeling, the demonstration that a single splicing factor modulates their pathological activation suggests that the post-transcriptional biology of these cells is a rich and underexplored therapeutic landscape.

Important caveats remain. PTBP1 is a pleiotropic regulator, and changing its dosage in fibroblasts will inevitably affect many targets, some beneficial and some not; translating the finding into a therapy will require identifying the specific isoform switches that carry the antifibrotic effect and finding selective ways to control them. Dose, timing, and cell-type specificity will all need careful optimization, and the long-term consequences of altering fibroblast splicing in a chronically stressed heart are unknown. Nevertheless, the study delivers a clear and consequential message: the heart’s scarring response is governed not only by which profibrotic genes are expressed, but by how their RNA is edited, and a single RNA-binding protein helps call those shots. In a field where therapeutic options for fibrosis remain limited, that is a lead worth pursuing.

Subject of Research: Role of the splicing factor PTBP1 in cardiac fibroblast profibrotic activation and alternative splicing.

Article Title: Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing

Article References: Ricketts, S. N., Farber, G. M., Verma, S. K., Dong, Y., Xie, Y., Takasugi, P. R., Chen, S., Du, L., Wang, H., Hui, W., Keles, C., Tsoy, S., Fuller, G., Wang, M., Gentile, G. M., Giudice, J., Kuyumcu-Martinez, M. N., Liu, J., & Qian, L. (2026). Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing. Nature Communications. https://doi.org/10.1038/s41467-026-77609-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77609-7

Keywords: PTBP1, cardiac fibroblasts, alternative splicing, cardiac fibrosis, TGF-beta, RNA-binding protein, myofibroblast, heart failure, splicing factors, extracellular matrix, Cardiac, fibroblast

The central idea behind the study is neuromodulation, the deliberate adjustment of nerve activity to change the function of an organ. For the heart, the relevant nerves belong to the autonomic nervous system, the network that operates largely outside conscious control. Sympathetic branches act like an accelerator, speeding the heart when the body demands more oxygen, while parasympathetic branches act as a brake, slowing it during rest and recovery. Clinicians have long known that adjusting this balance can treat rhythm disorders, but the tools available to do so have been crude, invasive, or both. Focused ultrasound offers a way to deliver energy to a precisely defined volume of tissue deep inside the body, stimulating or suppressing neural structures without any incision.

Ultrasound neuromodulation has attracted growing interest over the past decade because sound waves interact with tissue in ways that electrodes cannot. An ultrasound transducer can focus acoustic energy at a target millimeters across, several centimeters beneath the skin, while leaving intervening tissue essentially untouched. The mechanical and thermal effects of the focused beam can alter the excitability of nerve fibers, changing how likely they are to fire action potentials. Depending on the acoustic parameters chosen, the same technology can excite or inhibit neural activity, giving researchers a reversible dial for nervous system function rather than a simple on-off switch.

What distinguishes the new work is the emphasis on image guidance. Delivering energy to the region around the heart is technically demanding because the target moves constantly with each heartbeat and shifts with every breath. The researchers integrated their ultrasound system with imaging that allowed them to track and compensate for this motion, keeping the acoustic focus locked on the intended neural target as the body moved. This kind of closed-loop control is widely regarded as essential if ultrasound neuromodulation is ever to leave the laboratory, because even small targeting errors could disperse the acoustic energy to unintended structures or miss the nerve tissue altogether.

The reported outcome is that this image-guided stimulation could regulate heart rate. By directing focused ultrasound at cardiac neural targets, the team demonstrated that the technique could influence the pace of the heartbeat in a controlled fashion, adjusting the balance between the nerves that accelerate the heart and those that slow it. Regulation, rather than simple stimulation, is the crucial claim. A clinically useful therapy would need to raise or lower heart rate on demand, or damp pathological overactivity, and the study presents its approach as capable of that kind of bidirectional control.

The technical machinery required for this achievement is considerable. High-intensity focused ultrasound systems of the kind used for ablating tumors deliver enough energy to destroy tissue, but neuromodulation typically operates at far lower intensities, below thresholds that would cause lasting damage. The acoustic parameters, including frequency, pulse duration, and repetition rate, determine whether the beam primarily excites nerve fibers, suppresses them, or produces transient heating that changes their behavior. Finding parameter sets that reliably modulate cardiac nerves without harming the surrounding myocardium is one of the field’s central challenges, and the published work contributes data toward that goal.

Why does this matter for medicine? Disturbances of heart rate and rhythm are among the most common and lethal problems in clinical cardiology. Abnormally fast rhythms, abnormally slow rhythms, and chaotic fibrillation all arise from malfunctions in the heart’s electrical control system, and the autonomic nerves that supply the heart are deeply implicated in many of these conditions. Catheter ablation, in which a physician threads wires into the heart and burns small areas of tissue, is effective for some disorders but is invasive and carries procedural risk. Drugs can modulate autonomic tone but act throughout the body, producing side effects far from the heart. A noninvasive, focal, and reversible method for adjusting cardiac nerve activity would fill a genuine gap in the therapeutic arsenal.

The study also speaks to a broader trend in bioelectronic medicine, a field built on the idea that many diseases can be treated by adjusting the electrical signals carried by nerves rather than by delivering chemicals. Researchers have implanted electrodes on the vagus nerve to treat epilepsy and inflammatory conditions, and others have explored stimulation of the carotid sinus and spinal cord for cardiovascular indications. Ultrasound offers these same possibilities from outside the body, which would eliminate implantation surgery and infection risk. The heart, with its well-mapped autonomic innervation and its easily monitored output, is a natural proving ground for the concept, because heart rate itself provides an immediate, continuous readout of whether the neuromodulation is working.

As with any early-stage study, important questions remain before patients could benefit. The durability of the effect, the precise neural structures targeted, the safety margins for repeated sessions, and the translation of results across species are all matters that will require further investigation. The team’s own account presents the work as a demonstration of feasibility: that image guidance can keep a focused ultrasound beam on a moving cardiac target, and that the resulting neuromodulation is sufficient to regulate heart rate. Scaling from demonstration to therapy will demand larger and longer studies, refinement of the targeting algorithms, and careful assessment of any off-target effects on neighboring tissue.

Nevertheless, the publication marks a noteworthy step for a technology that many researchers hope will reshape how medicine interacts with the nervous system. The combination of focused ultrasound with real-time imaging transforms neuromodulation from a procedure requiring precision hardware implanted inside the body into something closer to an examination: the patient lies still, the imaging system tracks the target, and the acoustic beam delivers its influence without a single incision. If subsequent studies confirm and extend these results, the day may come when clinicians tune the heart’s rhythm the way this study did, with sound alone, guided by images, and reversed the moment the therapy ends.

The physics underlying this approach rewards a closer look, because it explains both the promise and the difficulty of the method. Ultrasound waves at the megahertz frequencies typically used for neuromodulation travel through soft tissue at roughly fifteen hundred meters per second and can be steered by phasing the emissions of hundreds of individual elements on a transducer array. Each element fires with a slightly different delay, so that the wavefronts arrive simultaneously at a chosen point, constructive interference concentrates the acoustic pressure there, and tissue elsewhere receives comparatively little energy. This electronic steering means the focus can be repositioned in milliseconds purely by changing the timing signals, a property that pairs naturally with the fast feedback demanded by a beating heart.

The choice of neural target is equally consequential. The heart’s autonomic control is organized around ganglionated plexi, clusters of neurons embedded in the epicardial fat pads near the pulmonary veins, the superior vena cava, and the atria. These microganglia act as local integration centers, relaying and processing signals from the vagus nerve and the sympathetic chain before they reach the cardiac conduction system. Cardiac surgeons and electrophysiologists have known for decades that disturbing these clusters alters atrial rhythm tendencies, which is precisely why they represent attractive targets for noninvasive modulation. Delivering acoustic energy to such small structures, however, requires submillimeter accuracy sustained over many cardiac cycles.

Motion compensation of this kind borrows heavily from techniques developed in radiation oncology, where tumor-tracking linear accelerators adjust beam delivery to a patient’s respiratory cycle. The cardiac problem is harder still, because the heart moves faster than the lungs and exhibits beat-to-beat variability. A successful tracking system must therefore anticipate where the target will be when each acoustic pulse arrives, rather than simply following its past position, and any latency in the imaging chain must be accounted for in the control algorithm.

Safety considerations extend beyond the avoidance of thermal injury. Regulatory frameworks for medical ultrasound, built around indices that estimate heating and the potential for cavitation, will need to be interpreted carefully for a therapy whose intended effect is functional rather than destructive. Repeated exposure of the same neural tissue raises questions about cumulative changes in nerve excitability, and the possibility that acoustic energy scattered by ribs or lung tissue could stimulate unintended structures deserves systematic study. The chest wall itself presents an acoustic obstacle, since bone reflects and absorbs ultrasound strongly, so coupling of the beam through an intercostal window is a practical constraint on positioning.

The experimental logic of using heart rate as an endpoint also deserves emphasis. Unlike modulation of deeper brain circuits, where effects must be inferred indirectly, cardiac neuromodulation produces a continuous, quantitative, beat-by-beat readout that can be captured with noninvasive electrocardiography. This tight feedback loop makes the heart an ideal model system for validating the principles of image-guided acoustic neuromodulation generally, and lessons learned here may well inform applications to the peripheral and central nervous system, where comparable targeting and monitoring challenges await solutions.

Subject of Research: Noninvasive image-guided focused ultrasound neuromodulation of cardiac autonomic nerves to regulate heart rate

Article Title: Image-guided cardiac focused ultrasound neuromodulation regulates heart rate

Article References: Piao, X., Wei, Y., Yao, X., Xu, Z., Pan, J.-J., Hu, P., & Cheng, B. (2026). Image-guided cardiac focused ultrasound neuromodulation regulates heart rate. Communications Engineering. https://doi.org/10.1038/s44172-026-00774-6

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00774-6

Keywords: focused ultrasound, neuromodulation, heart rate, autonomic nervous system, image guidance, cardiology, bioelectronic medicine, ultrasound therapy, cardiac nerves, noninvasive stimulation, Image-guided, cardiac